Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRekha, MR-
dc.contributor.authorPal, K-
dc.contributor.authorBala, P-
dc.contributor.authorShetty, M-
dc.contributor.authorMittra, I-
dc.contributor.authorBhuvaneshwar, GS-
dc.contributor.authorSharma, CP-
dc.identifier.citation34 ,27;6328-6338en_US
dc.description.abstractThe billions of cells that die in the adult human body daily release considerable amounts of fragmented chromatin in the form of mono- and oligonucleosomes into the circulation in normal individuals, and in higher quantities in many disease conditions. Recent results suggest that circulating chromatin fragments (Cfs) especially from abnormal cells can spontaneously enter into healthy cells to damage their DNA and induce genomic instability. Furthermore, Cfs isolated from cancer patients may induce oncogenic transformation in the recipients' cells. Thus, it follows that if such Cfs emanating from apoptotic cells could be prevented from reaching other cells, it could potentially inhibit pathological conditions, including cancer. Here we have developed pullulan based histone antibody nanoconjugates for the removal of Cfs. Nanoconjugates were developed and various physico-chemical characterizations were carried out. The efficacy of these nanoconjugates on removing Cfs was evaluated both in vitro and in vivo. Our results indicate that nanoconjugates may have therapeutic value in the efficient removal of Cfs, reducing inflammation and fatality in a mouse model of sepsis, and in preventing neutropenia following treatment with Adriamycin. (C) 2013 Elsevier Ltd. All rights reserved.-
dc.subjectEngineering; Materials Science-
dc.titlePullulan-histone antibody nanoconjugates for the removal of chromatin fragments from systemic circulation-
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.